Division of Hematology and Oncology, Department of Medicine
Letter to the Editor
Health Services Administration | Hemic and Lymphatic Diseases | Infectious Disease | Neoplasms | Oncology | Virus Diseases
Currently, the world is witnessing a health crisis in the form of COVID-19 pandemic. For oncologists, especially for stem cell transplant specialists, the stress is high to perform to their best of capability for their cancer patients. In general, the hematopoietic stem cell transplantation (HSCT) is a high-risk procedure. The novelty of the COVID-19 disease, lack of literature, absence of antiviral agent, and vaccine has added more uncertainty while preparing for and recovering from HSCT.
COVID-19, pandemic, hematopoietic stem cell transplantation, oncologists, guidelines
Rights and Permissions
Copyright © Springer Nature Limited 2020. Publisher PDF posted after 6 month embargo as allowed by the publisher's self-archiving policy athttps://www.nature.com/bmt/authors-and-referees/open-access-self-archiving.
DOI of Published Version
Sahu KK, Siddiqui AD, Cerny J. COVID-19 pandemic and impact on hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020 May 4:1–3. doi: 10.1038/s41409-020-0913-6. Epub ahead of print. PMID: 32367075; PMCID: PMC7197237. Link to article on publisher's site
Bone marrow transplantation
Sahu KK, Siddiqui AD, Cerny J. (2020). COVID-19 pandemic and impact on hematopoietic stem cell transplantation. Coronavirus COVID-19 Publications by UMMS Authors. https://doi.org/10.1038/s41409-020-0913-6. Retrieved from https://escholarship.umassmed.edu/covid19/27
Available for download on Wednesday, November 04, 2020